Breast Cancer

Key clinical point: Margetuximab failed to demonstrate a survival advantage over trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (BC).

Major finding: After a median follow-up of 20.2 months, no benefit in overall survival (OS) was observed with margetuximab vs trastuzumab (hazard ratio [HR] 0.95; P = .620). The safety profile of margetuximab was acceptable and comparable to that of trastuzumab.

Study details: Findings are from the phase 3 SOPHIA study including 536 patients with HER2+ advanced BC who received ≥2 prior anti-HER2 regimens and were randomly assigned to receive chemotherapy with margetuximab or trastuzumab.

Disclosures: This study was supported by MacroGenics, Inc. The authors declared serving as employees, consultants, or on speaker’s bureaus, holding stock options, or receiving honoraria, research funding, or travel or accommodation expenses from several sources, including MacroGenics.

Source: Rugo HS et al  on behalf of the SOPHIA Study Group. Margetuximab versus trastuzumab in patients with previously treated her2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2022 (Nov 4). Doi: 10.1200/JCO.21.02937

Key clinical point: Margetuximab failed to demonstrate a survival advantage over trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (BC).

Major finding: After a median follow-up of 20.2 months, no benefit in overall survival (OS) was observed with margetuximab vs trastuzumab (hazard ratio [HR] 0.95; P = .620). The safety profile of margetuximab was acceptable and comparable to that of trastuzumab.

Study details: Findings are from the phase 3 SOPHIA study including 536 patients with HER2+ advanced BC who received ≥2 prior anti-HER2 regimens and were randomly assigned to receive chemotherapy with margetuximab or trastuzumab.

Disclosures: This study was supported by MacroGenics, Inc. The authors declared serving as employees, consultants, or on speaker’s bureaus, holding stock options, or receiving honoraria, research funding, or travel or accommodation expenses from several sources, including MacroGenics.

Source: Rugo HS et al  on behalf of the SOPHIA Study Group. Margetuximab versus trastuzumab in patients with previously treated her2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2022 (Nov 4). Doi: 10.1200/JCO.21.02937

Key clinical point: Margetuximab failed to demonstrate a survival advantage over trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (BC).

Major finding: After a median follow-up of 20.2 months, no benefit in overall survival (OS) was observed with margetuximab vs trastuzumab (hazard ratio [HR] 0.95; P = .620). The safety profile of margetuximab was acceptable and comparable to that of trastuzumab.

Study details: Findings are from the phase 3 SOPHIA study including 536 patients with HER2+ advanced BC who received ≥2 prior anti-HER2 regimens and were randomly assigned to receive chemotherapy with margetuximab or trastuzumab.

Disclosures: This study was supported by MacroGenics, Inc. The authors declared serving as employees, consultants, or on speaker’s bureaus, holding stock options, or receiving honoraria, research funding, or travel or accommodation expenses from several sources, including MacroGenics.

Source: Rugo HS et al  on behalf of the SOPHIA Study Group. Margetuximab versus trastuzumab in patients with previously treated her2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2022 (Nov 4). Doi: 10.1200/JCO.21.02937

Key clinical point: The risk for uterine diseases was significantly increased in premenopausal women with breast cancer (BC) who received tamoxifen as an adjuvant hormone therapy.

Major finding: Compared with patients who did not receive adjuvant hormone therapy, those who received tamoxifen had a significantly higher risk for endometrial cancer (hazard ratio [HR] 3.77; 95% CI 3.04-4.66), endometrial polyps (HR 3.90; 95% CI 3.65-4.16), hyperplasia (HR 5.56; 95% CI 5.06-6.12), and other uterine cancers (HR 2.27; 95% CI 1.54-3.33).

Study details: Findings are from a nationwide, retrospective, longitudinal cohort study including 78,320 premenopausal women with BC who received (tamoxifen only; n = 34,637) or did not receive (n = 43,683) an adjuvant hormone treatment.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Ryu KJ et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open. 2022 5(11):e2243951 (Nov 28). Doi: 10.1001/jamanetworkopen.2022.43951

Key clinical point: The risk for uterine diseases was significantly increased in premenopausal women with breast cancer (BC) who received tamoxifen as an adjuvant hormone therapy.

Major finding: Compared with patients who did not receive adjuvant hormone therapy, those who received tamoxifen had a significantly higher risk for endometrial cancer (hazard ratio [HR] 3.77; 95% CI 3.04-4.66), endometrial polyps (HR 3.90; 95% CI 3.65-4.16), hyperplasia (HR 5.56; 95% CI 5.06-6.12), and other uterine cancers (HR 2.27; 95% CI 1.54-3.33).

Study details: Findings are from a nationwide, retrospective, longitudinal cohort study including 78,320 premenopausal women with BC who received (tamoxifen only; n = 34,637) or did not receive (n = 43,683) an adjuvant hormone treatment.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Ryu KJ et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open. 2022 5(11):e2243951 (Nov 28). Doi: 10.1001/jamanetworkopen.2022.43951

Key clinical point: The risk for uterine diseases was significantly increased in premenopausal women with breast cancer (BC) who received tamoxifen as an adjuvant hormone therapy.

Major finding: Compared with patients who did not receive adjuvant hormone therapy, those who received tamoxifen had a significantly higher risk for endometrial cancer (hazard ratio [HR] 3.77; 95% CI 3.04-4.66), endometrial polyps (HR 3.90; 95% CI 3.65-4.16), hyperplasia (HR 5.56; 95% CI 5.06-6.12), and other uterine cancers (HR 2.27; 95% CI 1.54-3.33).

Study details: Findings are from a nationwide, retrospective, longitudinal cohort study including 78,320 premenopausal women with BC who received (tamoxifen only; n = 34,637) or did not receive (n = 43,683) an adjuvant hormone treatment.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Ryu KJ et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open. 2022 5(11):e2243951 (Nov 28). Doi: 10.1001/jamanetworkopen.2022.43951

Key clinical point: The addition of weekly carboplatin to standard anthracycline-weekly paclitaxel-based neoadjuvant chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).

Major finding: The rate of pCR was significantly higher in the anthracycline-paclitaxel+carboplatin vs anthracycline-paclitaxel treatment group (51.9% vs 34.2%; odds ratio 2.40; P = .01); however, no significant differences were observed in grade ≥3 hematological toxicities between both groups.

Study details: Findings are from a multicenter study including 247 patients with TNBC who received sequential treatment with anthracycline and weekly paclitaxel with or without weekly carboplatin.

Disclosures: This study was supported by the Italian Ministry of Health. The authors declared receiving personal fees, grants, or non-financial support from several sources.

Source: Dieci MV et al. Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: Propensity-score matching analysis and TIL evaluation. Br J Cancer. 2022 (Nov 17). Doi: 10.1038/s41416-022-02050-8

Key clinical point: The addition of weekly carboplatin to standard anthracycline-weekly paclitaxel-based neoadjuvant chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).

Major finding: The rate of pCR was significantly higher in the anthracycline-paclitaxel+carboplatin vs anthracycline-paclitaxel treatment group (51.9% vs 34.2%; odds ratio 2.40; P = .01); however, no significant differences were observed in grade ≥3 hematological toxicities between both groups.

Study details: Findings are from a multicenter study including 247 patients with TNBC who received sequential treatment with anthracycline and weekly paclitaxel with or without weekly carboplatin.

Disclosures: This study was supported by the Italian Ministry of Health. The authors declared receiving personal fees, grants, or non-financial support from several sources.

Source: Dieci MV et al. Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: Propensity-score matching analysis and TIL evaluation. Br J Cancer. 2022 (Nov 17). Doi: 10.1038/s41416-022-02050-8

Key clinical point: The addition of weekly carboplatin to standard anthracycline-weekly paclitaxel-based neoadjuvant chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).

Major finding: The rate of pCR was significantly higher in the anthracycline-paclitaxel+carboplatin vs anthracycline-paclitaxel treatment group (51.9% vs 34.2%; odds ratio 2.40; P = .01); however, no significant differences were observed in grade ≥3 hematological toxicities between both groups.

Study details: Findings are from a multicenter study including 247 patients with TNBC who received sequential treatment with anthracycline and weekly paclitaxel with or without weekly carboplatin.

Disclosures: This study was supported by the Italian Ministry of Health. The authors declared receiving personal fees, grants, or non-financial support from several sources.

Source: Dieci MV et al. Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: Propensity-score matching analysis and TIL evaluation. Br J Cancer. 2022 (Nov 17). Doi: 10.1038/s41416-022-02050-8

Key clinical point: Breast cancer (BC) survivors who were active or moderately active had an ~60% lower risk for mortality compared with those who were insufficiently active.

Major finding: Compared with insufficiently active participants, the risk for mortality was ~60% lower in active (hazard ratio [HR] 0.42; 95% CI 0.21-0.85) and moderately active (HR 0.40; 95% CI 0.17-0.95) participants.

Study details: Findings are from a cohort study including 315 postmenopausal BC survivors who were followed for a minimum of 2 years post-diagnosis.

Disclosures: This study was supported by the US National Cancer Institute. The authors declared no conflicts of interest.

Source: Chen LH et al. Association of physical activity with risk of mortality among breast cancer survivors. JAMA Netw Open. 2022;5(11):e2242660 (Nov 17). Doi: 10.1001/jamanetworkopen.2022.42660

Key clinical point: Breast cancer (BC) survivors who were active or moderately active had an ~60% lower risk for mortality compared with those who were insufficiently active.

Major finding: Compared with insufficiently active participants, the risk for mortality was ~60% lower in active (hazard ratio [HR] 0.42; 95% CI 0.21-0.85) and moderately active (HR 0.40; 95% CI 0.17-0.95) participants.

Study details: Findings are from a cohort study including 315 postmenopausal BC survivors who were followed for a minimum of 2 years post-diagnosis.

Disclosures: This study was supported by the US National Cancer Institute. The authors declared no conflicts of interest.

Source: Chen LH et al. Association of physical activity with risk of mortality among breast cancer survivors. JAMA Netw Open. 2022;5(11):e2242660 (Nov 17). Doi: 10.1001/jamanetworkopen.2022.42660

Key clinical point: Breast cancer (BC) survivors who were active or moderately active had an ~60% lower risk for mortality compared with those who were insufficiently active.

Major finding: Compared with insufficiently active participants, the risk for mortality was ~60% lower in active (hazard ratio [HR] 0.42; 95% CI 0.21-0.85) and moderately active (HR 0.40; 95% CI 0.17-0.95) participants.

Study details: Findings are from a cohort study including 315 postmenopausal BC survivors who were followed for a minimum of 2 years post-diagnosis.

Disclosures: This study was supported by the US National Cancer Institute. The authors declared no conflicts of interest.

Source: Chen LH et al. Association of physical activity with risk of mortality among breast cancer survivors. JAMA Netw Open. 2022;5(11):e2242660 (Nov 17). Doi: 10.1001/jamanetworkopen.2022.42660

Key clinical point: Trastuzumab deruxtecan demonstrated superior survival outcomes compared with trastuzumab emtansine in the second-line setting and also had a manageable safety profile in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: Trastuzumab deruxtecan vs trastuzumab emtansine resulted in a ~36% reduction in the risk for death (hazard ratio 0.64; P = .0037) and the longest reported improvement in progression-free survival (28.8 months vs 6.8 months; nominal P < .0001). The rate of grade ≥3 adverse events was similar with trastuzumab deruxtecan vs trastuzumab emtansine (56% vs 52%).

Study details: Findings are from the phase 3, DESTINY-Breast03 trial including 524 patients with HER2+ metastatic BC who had progressed during or after treatment with trastuzumab and a taxane and were randomly assigned to receive trastuzumab deruxtecan or trastuzumab emtansine.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Four authors declared being employees or stockholders of Daiichi Sankyo, and the other authors reported ties with various sources, including Daiichi Sankyo and AstraZeneca.

Source: Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022 (Dec 7). Doi: 10.1016/S0140-6736(22)02420-5

Key clinical point: Trastuzumab deruxtecan demonstrated superior survival outcomes compared with trastuzumab emtansine in the second-line setting and also had a manageable safety profile in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: Trastuzumab deruxtecan vs trastuzumab emtansine resulted in a ~36% reduction in the risk for death (hazard ratio 0.64; P = .0037) and the longest reported improvement in progression-free survival (28.8 months vs 6.8 months; nominal P < .0001). The rate of grade ≥3 adverse events was similar with trastuzumab deruxtecan vs trastuzumab emtansine (56% vs 52%).

Study details: Findings are from the phase 3, DESTINY-Breast03 trial including 524 patients with HER2+ metastatic BC who had progressed during or after treatment with trastuzumab and a taxane and were randomly assigned to receive trastuzumab deruxtecan or trastuzumab emtansine.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Four authors declared being employees or stockholders of Daiichi Sankyo, and the other authors reported ties with various sources, including Daiichi Sankyo and AstraZeneca.

Source: Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022 (Dec 7). Doi: 10.1016/S0140-6736(22)02420-5

Key clinical point: Trastuzumab deruxtecan demonstrated superior survival outcomes compared with trastuzumab emtansine in the second-line setting and also had a manageable safety profile in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: Trastuzumab deruxtecan vs trastuzumab emtansine resulted in a ~36% reduction in the risk for death (hazard ratio 0.64; P = .0037) and the longest reported improvement in progression-free survival (28.8 months vs 6.8 months; nominal P < .0001). The rate of grade ≥3 adverse events was similar with trastuzumab deruxtecan vs trastuzumab emtansine (56% vs 52%).

Study details: Findings are from the phase 3, DESTINY-Breast03 trial including 524 patients with HER2+ metastatic BC who had progressed during or after treatment with trastuzumab and a taxane and were randomly assigned to receive trastuzumab deruxtecan or trastuzumab emtansine.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Four authors declared being employees or stockholders of Daiichi Sankyo, and the other authors reported ties with various sources, including Daiichi Sankyo and AstraZeneca.

Source: Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022 (Dec 7). Doi: 10.1016/S0140-6736(22)02420-5

Key clinical point: A dose-escalation schema of everolimus plus exemestane was more effective than conventionally administered everolimus (10 mg) plus exemestane in reducing grade ≥2 stomatitis in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC).

Major finding: Within 12 weeks, the incidence of grade ≥2 stomatitis episodes was significantly lower in the everolimus dose escalation vs the 10 mg everolimus arm (odds ratio 0.47; P = .026). Except for stomatitis, toxicity was not significantly different between both treatment arms.

Study details: Findings are from the phase 2, DESIREE trial including 160 postmenopausal women with HR+/HER2− mBC who were randomly assigned to receive exemestane with an escalating dose of everolimus (2.5, 5, 7.5, and 10 mg/day at weeks 1, 2, 3, and 4-24, respectively) or 10 mg/day everolimus.

Disclosures: This study was funded by Novartis, Germany. The authors declared receiving personal fees, grants, consulting fees, honoraria, or support for attending meetings or travel from several sources, including Novartis.

Source: Schmidt M et al. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). ESMO Open. 2022;7(6):100601 (Nov 7). Doi: 10.1016/j.esmoop.2022.100601

Key clinical point: A dose-escalation schema of everolimus plus exemestane was more effective than conventionally administered everolimus (10 mg) plus exemestane in reducing grade ≥2 stomatitis in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC).

Major finding: Within 12 weeks, the incidence of grade ≥2 stomatitis episodes was significantly lower in the everolimus dose escalation vs the 10 mg everolimus arm (odds ratio 0.47; P = .026). Except for stomatitis, toxicity was not significantly different between both treatment arms.

Study details: Findings are from the phase 2, DESIREE trial including 160 postmenopausal women with HR+/HER2− mBC who were randomly assigned to receive exemestane with an escalating dose of everolimus (2.5, 5, 7.5, and 10 mg/day at weeks 1, 2, 3, and 4-24, respectively) or 10 mg/day everolimus.

Disclosures: This study was funded by Novartis, Germany. The authors declared receiving personal fees, grants, consulting fees, honoraria, or support for attending meetings or travel from several sources, including Novartis.

Source: Schmidt M et al. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). ESMO Open. 2022;7(6):100601 (Nov 7). Doi: 10.1016/j.esmoop.2022.100601

Key clinical point: A dose-escalation schema of everolimus plus exemestane was more effective than conventionally administered everolimus (10 mg) plus exemestane in reducing grade ≥2 stomatitis in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC).

Major finding: Within 12 weeks, the incidence of grade ≥2 stomatitis episodes was significantly lower in the everolimus dose escalation vs the 10 mg everolimus arm (odds ratio 0.47; P = .026). Except for stomatitis, toxicity was not significantly different between both treatment arms.

Study details: Findings are from the phase 2, DESIREE trial including 160 postmenopausal women with HR+/HER2− mBC who were randomly assigned to receive exemestane with an escalating dose of everolimus (2.5, 5, 7.5, and 10 mg/day at weeks 1, 2, 3, and 4-24, respectively) or 10 mg/day everolimus.

Disclosures: This study was funded by Novartis, Germany. The authors declared receiving personal fees, grants, consulting fees, honoraria, or support for attending meetings or travel from several sources, including Novartis.

Source: Schmidt M et al. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). ESMO Open. 2022;7(6):100601 (Nov 7). Doi: 10.1016/j.esmoop.2022.100601

Key clinical point: Obesity and advanced stage (stage III) at diagnosis of breast cancer (BC) were associated with a higher rate of recurrence and worse prognosis in patients with BC who achieved pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NCT).

Major finding: Obesity vs  no obesity (P = .019) and stage III vs  stage I-II BC at diagnosis (P = .0018) were significantly associated with worse invasive disease-free survival, with obesity demonstrating worse survival outcomes in stage III BC (hazard ratio 4.31; P = .006).

Study details: Findings are from a retrospective real-world analysis including 241 patients with stage I-III BC who had achieved pCR after receiving NCT.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Acevedo F et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12:21145 (Dec 7). Doi: 10.1038/s41598-022-25043-2

Key clinical point: Obesity and advanced stage (stage III) at diagnosis of breast cancer (BC) were associated with a higher rate of recurrence and worse prognosis in patients with BC who achieved pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NCT).

Major finding: Obesity vs  no obesity (P = .019) and stage III vs  stage I-II BC at diagnosis (P = .0018) were significantly associated with worse invasive disease-free survival, with obesity demonstrating worse survival outcomes in stage III BC (hazard ratio 4.31; P = .006).

Study details: Findings are from a retrospective real-world analysis including 241 patients with stage I-III BC who had achieved pCR after receiving NCT.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Acevedo F et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12:21145 (Dec 7). Doi: 10.1038/s41598-022-25043-2

Key clinical point: Obesity and advanced stage (stage III) at diagnosis of breast cancer (BC) were associated with a higher rate of recurrence and worse prognosis in patients with BC who achieved pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NCT).

Major finding: Obesity vs  no obesity (P = .019) and stage III vs  stage I-II BC at diagnosis (P = .0018) were significantly associated with worse invasive disease-free survival, with obesity demonstrating worse survival outcomes in stage III BC (hazard ratio 4.31; P = .006).

Study details: Findings are from a retrospective real-world analysis including 241 patients with stage I-III BC who had achieved pCR after receiving NCT.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Acevedo F et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12:21145 (Dec 7). Doi: 10.1038/s41598-022-25043-2

Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.

Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs  maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).

Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365

Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.

Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs  maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).

Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365

Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.

Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs  maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).

Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365

Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.

Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs  maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).

Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365

Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.

Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs  maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).

Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365

Key clinical point: A substantial proportion of patients showed receptor conversion between primary breast cancer (BC) and bone metastases, which significantly impacted prognosis.

Major finding: The discordance rates between primary BC and bone metastases were 14.0%, 32.3%, and 9.7% for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), respectively. The loss vs  maintenance of hormone receptor expression was associated with worse first-line progression-free survival (adjusted hazard ratio [aHR] 3.27; P = .039) and overall survival (aHR 6.09; P = .011).

Study details: Findings are from a retrospective analysis including 93 patients with BC, pathologically confirmed bone metastasis, and ER, PgR, and HER2 status available on both primary tumor and bone metastases.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Lin M et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2022 (Nov 21). Doi: 10.1002/ijc.34365

Key clinical point: Selective internal radiation therapy (SIRT) with ⁹⁰Y demonstrated favorable survival benefits in patients with breast cancer (BC) and hepatic metastasis, particularly in those with low liver tumor burden and without extrahepatic metastasis.

Major finding: Postembolization median survival time (MST) was 9.8 months, with MST being significantly higher in patients with <25% vs  >25% hepatic metastatic burden (10.5 vs  6.8 months; P < .0001) and localized vs  additional hepatic metastasis (15.0 vs  5.3 months; P < .0001). None of the adverse events were life-threatening.

Study details: Findings are from a meta-analysis of 24 studies including 412 patients with metastatic BC and hepatic metastasis who had received SIRT.

Disclosures: This study was funded by the Natural Science Foundation of Shandong Province, China. The authors declared no conflicts of interest.

Source: Liu C et al. Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis. Front Oncol. 2022;12:887653 (Nov 24). Doi: 10.3389/fonc.2022.887653

Key clinical point: Selective internal radiation therapy (SIRT) with ⁹⁰Y demonstrated favorable survival benefits in patients with breast cancer (BC) and hepatic metastasis, particularly in those with low liver tumor burden and without extrahepatic metastasis.

Major finding: Postembolization median survival time (MST) was 9.8 months, with MST being significantly higher in patients with <25% vs  >25% hepatic metastatic burden (10.5 vs  6.8 months; P < .0001) and localized vs  additional hepatic metastasis (15.0 vs  5.3 months; P < .0001). None of the adverse events were life-threatening.

Study details: Findings are from a meta-analysis of 24 studies including 412 patients with metastatic BC and hepatic metastasis who had received SIRT.

Disclosures: This study was funded by the Natural Science Foundation of Shandong Province, China. The authors declared no conflicts of interest.

Source: Liu C et al. Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis. Front Oncol. 2022;12:887653 (Nov 24). Doi: 10.3389/fonc.2022.887653

Key clinical point: Selective internal radiation therapy (SIRT) with ⁹⁰Y demonstrated favorable survival benefits in patients with breast cancer (BC) and hepatic metastasis, particularly in those with low liver tumor burden and without extrahepatic metastasis.

Major finding: Postembolization median survival time (MST) was 9.8 months, with MST being significantly higher in patients with <25% vs  >25% hepatic metastatic burden (10.5 vs  6.8 months; P < .0001) and localized vs  additional hepatic metastasis (15.0 vs  5.3 months; P < .0001). None of the adverse events were life-threatening.

Study details: Findings are from a meta-analysis of 24 studies including 412 patients with metastatic BC and hepatic metastasis who had received SIRT.

Disclosures: This study was funded by the Natural Science Foundation of Shandong Province, China. The authors declared no conflicts of interest.

Source: Liu C et al. Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis. Front Oncol. 2022;12:887653 (Nov 24). Doi: 10.3389/fonc.2022.887653